Dr. Reddy's Laboratories Ltd.

396 articles with Dr. Reddy's Laboratories Ltd.

• Dr. Reddy’s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overall Survival Through a Combination of E7777 (Denileukin Diftitox) and an Immune Checkpoint Inhibitor

  11/9/2020

  Dr. Reddy’s Laboratories Ltd. announced a preclinical data presentation for E7777, its engineered IL-2-diphtheria toxin fusion protein, at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting, being held virtually.

• Dr. Reddy's partners with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India

  10/29/2020

  Dr. Reddy’s Laboratories Ltd., announced its partnership with Biotechnology Industry Research Assistance Council, Department of Biotechnology, Government of India, for advisory support on clinical trials of Sputnik V vaccine in India.

• Dr. Reddy’s Q2 & H1 FY21 Financial Results

  10/28/2020

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter and the half year ended September 30, 2020.

• Dr. Reddy's Laboratories Announces Appointment of New Chief Financial Officer

  10/28/2020

  Dr. Reddy’s Laboratories Ltd. announced that Parag Agarwal will be joining the Company as Chief Financial Officer on November 2, 2020.

• Dr. Reddy’s announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC® in the U.S. Market

  10/20/2020

  Dr. Reddy’s Laboratories Ltd. announced the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, the store-brand equivalents of Original Strength and Maximum Strength Pepcid AC®, in the U.S. market, as approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India

  10/17/2020

  Dr. Reddy’s Laboratories Ltd. and Russian Direct Investment Fund, Russia’s sovereign wealth fund, announced that they have received approval from the Drug Control General of India to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India.

• Dr. Reddy’s Laboratories Joins Science Based Targets initiative (SBTi) and Sets 2030 GHG Emission Targets

  10/5/2020

  Dr. Reddy’s Laboratories Ltd. has joined the Science Based Targets initiative’s business ambition for 1.5°C, becoming the first Indian and the third Asian pharmaceutical company to have set its Science-Based Targets to further minimize environmental impact.

• Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market

  10/3/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use.

• Dr. Reddy's Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. Market

  10/1/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar Tablets, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Dimethyl Fumarate Delayed-Release Capsules in the U.S. Market

  9/26/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera® Delayed-Release Capsules, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market

  9/25/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex® in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday®, the Eye Allergy Drop in the U.S. Market

  9/17/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of over-the-counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalents of Pataday® Once Daily Relief and Pataday® Twice Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration.

• RDIF and Dr. Reddy's to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to India

  9/16/2020

  The Russian Direct Investment Fund, Russia's sovereign wealth fund, and Dr. Reddy's Laboratories Ltd., a global pharmaceutical company headquartered out of India, have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India.

• Dr. Reddy's Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market

  9/9/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of over-the-counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. market.

• Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. Market

  9/7/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Fulvestrant Injection, 250 mg/5 mL per Single-dose Syringe, a therapeutic equivalent generic version of Faslodex® Injection, 250 mg/5 mL, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market

  9/3/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a therapeutic equivalent generic version of Concerta® Extended-Release Tablets, 18 mg, 27 mg, 36 mg, and 54 mg, approved by the U.S.

• Dr. Reddy's Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. Market

  8/27/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine® Capsules, 250 mg, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories announces the launch of AVIGAN® (Favipiravir) in India

  8/19/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of AVIGAN® 200 mg Tablets in India.

• Dr. Reddy's Laboratories announces the First-to-Market launch of the generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, USP in the U.S. Market

  8/11/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex® Otic Suspension, approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s Q1 FY21 Financial Results

  7/29/2020

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter ended June 30, 2020.